Apheresis Market Size, Growth & Trends by 2034

The apheresis market was valued at US$ 2.97 Billion in 2025 and is projected to reach US$ 6.04 Billion by 2034, expanding at a CAGR of 8.20% during 2026–2034. The market encompasses devices and disposables used across donor and therapeutic procedures, including leukapheresis, plasmapheresis, plateletpheresis, and erythrocytapheresis, supported by centrifugation and membrane separation technologies across renal, hematological, neurological, and autoimmune applications.

North America remains a structurally important geography, supported by established blood-component collection networks, specialized therapeutic centers, advanced hospital infrastructure, and comparatively developed reimbursement mechanisms. The regional Apheresis Market Size is estimated to expand at a CAGR of 7.5–8.5% during 2026–2034, with demand increasingly influenced by plasma collection, cell therapy manufacturing, neurological applications, and replacement of installed equipment.

Apheresis Market Assessment and Insights

The apheresis market has evolved from predominantly capital-equipment-led procurement toward integrated systems combining automated separation, single-use circuits, sensors, software, and procedure-specific disposables. Production approaches now focus on developing closed system designs and high-throughput disposables, with manufacturers improving upon their separation precision, throughput efficiency, ease of use, and ability to be integrated into ever more sophisticated therapeutic and cellular processes.

In terms of future adoption, usage will expand in the new Asian and certain Middle Eastern healthcare systems, where hospitals develop the infrastructure for blood component processing and advanced therapies. Regulatory modernization, cell and gene therapy expansion, and plasma and blood products investment will help drive both replacement and continuous disposable needs.

Apheresis Market Report Scope

Apheresis Market Analysis

Demand is shaped by the intersection of blood-component requirements and therapeutic indications, as highlighted in the Apheresis Market Report. Plasma, platelets, leukocytes, and red-cell collection create recurring procedural requirements, while autoimmune, neurological, renal, and hematological disorders support therapeutic applications. The value chain consists of device manufacture, kit production, provision of anticoagulants and tubing, hospital purchasing, blood center activities, procedure performance, and post-sale services.

In light of this, market supply is in favor of companies that can deliver reliable devices along with their proprietary consumable systems. Typically, apheresis devices need to undergo special engineering, regulatory testing, software control, and procedure-specific disposables, making it challenging to switch providers once installed. Moreover, hospitals assess the cost per procedure, uptime, training needs, serviceability, and consumables availability.

The competitive environment is centered on the existing organizations that have a large customer base and a specific technological portfolio. Terumo Blood and Cell Technologies, Inc. competes in terms of blood components and therapeutic apheresis solutions, while Haemonetics Corporation is strongly exposed to the plasma and blood center business. Fresenius SE & Co. KGaA and B. Braun Melsungen AG have a strong presence in the blood processing and medical devices environment, while Asahi Kasei Medical Co., Ltd. holds a strong position in therapeutic blood purification.

Investment is increasingly directed toward automation, cell-processing compatibility, digital workflow management, and production capacity for disposable components. According to the Apheresis Market Forecast, these trends are expected to strengthen operational efficiency and support expanding clinical applications. Baxter International Inc., Cerus Corporation, Kaneka Corporation, Kawasumi Laboratories, Inc., and Nikkiso Co., Ltd. contribute additional competitive depth through specialized technologies and regional distribution capabilities. Strategic positioning increasingly depends on clinical evidence, regulatory reach, recurring consumables, service infrastructure, and the ability to support emerging cell and gene therapy workflows.

Apheresis Market: Strategic Insights

Regional Insights

North America Apheresis Market

North America represented approximately 34–37% of the apheresis market share in 2025 and is expected to grow at a CAGR of 7.5–8.5% through 2034. The largest portion of regional demand is contributed by the United States owing to the development of blood banks, specialized hospitals, apheresis therapies, and plasma collection infrastructure. Canada provides its contribution through tertiary hospitals and transfusion services.

The regional market opportunity is not only limited to the traditional collection of blood components but also includes other applications as well, including therapeutic procedures in neurological and autoimmune disorders, as well as the manufacture of cell therapies that depend on the collection of cellular material. Replacement of aging equipment, disposable circuits, operator training, and service agreements should drive the recurring revenues.

U.S. Apheresis Market

The U.S. represented approximately 86–89% of North America's 2025 apheresis market and is projected to grow at a CAGR of 7.4–8.4% through 2034. The nation enjoys a well-developed system of blood center facilities, specialty hospitals, plasma collection centers, and an installed base. The major companies operate both commercial and service networks within the country.

Applications cover platelet and plasma collection, leukapheresis for cell processing and therapy of neurological disorders, kidneys, autoimmune, and hematology diseases. Companies like Terumo Blood and Cell Technologies, Inc., Haemonetics Corporation, and Fresenius SE & Co. KGaA compete by means of platform technology, disposables, services, and workflow.

Europe Apheresis Market

Europe held approximately 25–28% of the apheresis market in 2025 and is projected to expand at a CAGR of 7.6–8.6%. Germany is the largest market, backed by a well-developed transfusion infrastructure and therapies. The United Kingdom and France have developed clinical programs, whereas Italy and Spain are contributing through hospital-based activities and blood component supply.

Germany is benefited by advanced hospital setups and medical device technology, thereby demanding automated devices, disposable items for procedures, and services. The United Kingdom is emphasizing the efficient use of blood components and therapies. France, Italy, and Spain contribute through the demand from tertiary hospitals, transfusion centers, and clinical programs.

APAC Apheresis Market

APAC accounted for approximately 22–25% of the apheresis market in 2025 and is expected to grow at a CAGR of 9.2–10.2%, making it the fastest-expanding major region. China is the largest market for the technology in the region, followed by Japan, South Korea, India, and Australia, where the healthcare sector is modernized and improved in terms of adoption.

China has expanding hospital capacity coupled with domestic development of medical devices, whereas Japan is able to enjoy clinical infrastructure that is well-developed. South Korea and India provide good market opportunities as blood-processing and therapy technologies advance. Australia can still rely on the transfusion infrastructure.

Middle East & Africa Apheresis Market

The Middle East & Africa Apheresis Market is expected to record a CAGR of 6.8–7.8% through 2034, with Saudi Arabia leading regional development, followed by the UAE and South Africa. Specialized hospitals and national healthcare modernization programs are expanding access to complex blood-processing services.

Saudi Arabia and the UAE benefit from large tertiary-care investments and advanced private healthcare capacity, while South Africa serves as an important clinical hub. The rest of MEA remains more infrastructure-constrained, making centralized blood centers and referral hospitals important procurement points. Energy-sector investment supports healthcare infrastructure in Gulf economies, while public-private projects can improve the availability of specialized procedures.

Segmentation Analysis

Product

Product demand is divided between Devices and Disposables, with Disposables representing the largest recurring revenue pool. Key Apheresis Market Trends indicate that the segment is projected to grow at a CAGR of 7.5–8.5% during 2026–2034. Equipment replacement, procedure automation, infection-control requirements, and proprietary consumable compatibility influence purchasing decisions. Disposable utilization rises with procedure volumes because tubing sets, collection components, filters, and associated circuits are generally consumed on a procedure-specific basis.

• Devices: Automated separation platforms remain strategically important because they establish installed-base relationships and determine compatibility with procedure-specific consumables. Hospitals increasingly prioritize automation, reliability, software controls, operator guidance, and service support when replacing capital equipment.
• Disposables: Recurring kits, tubing assemblies, filters, and collection components represent essential per-procedure requirements. Their importance increases with procedure volumes and reinforces supplier retention because validated consumable-device compatibility can influence operational continuity.

Apheresis Procedure

The Apheresis Procedure segment of the Apheresis Market includes Leukapheresis, Plasmapheresis, Plateletpheresis, Erythrocytapheresis, and Other Apheresis Procedures. The segment is projected to expand at a CAGR of 7.8–8.8% during 2026–2034. Growth reflects the coexistence of donor procedures and therapeutic applications, with procedure selection determined by the blood component targeted, clinical indication, and treatment protocol. Increasing specialization is broadening demand beyond traditional collection workflows.

• Leukapheresis: Demand is strategically linked to cellular collection and therapeutic applications, particularly where controlled white-cell removal or collection is required. Increasing cellular therapy activity supports continued utilization of dedicated collection workflows.
• Plasmapheresis: Plasma separation remains a major procedural category across donor and therapeutic settings. Its importance is reinforced by plasma-derived product requirements and clinical use in selected autoimmune, neurological, and renal conditions.
• Plateletpheresis: Platelet collection supports transfusion services requiring targeted component procurement. Single-donor platelet workflows can improve component management and remain important for hospitals and blood centers seeking predictable platelet availability.
• Erythrocytapheresis: Red-cell exchange is clinically specialized and concentrated in selected patient populations. Its strategic relevance derives from repeated therapeutic procedures where controlled removal and replacement of red-cell components are clinically required.

Technology

Technology comprises Centrifugation and Membrane Separation, with the segment projected to grow at a CAGR of 8.0–9.0% during 2026–2034. Technology selection depends on target component, procedure type, throughput, clinical protocol, and equipment design. Automation, sensor integration, improved separation control, and operator guidance are increasingly important differentiators, while membrane systems remain valuable where selective filtration characteristics support therapeutic applications.

• Centrifugation: Centrifugation separates blood components according to density and remains central to donor and therapeutic workflows. Automated control, continuous monitoring, and adaptable operating parameters strengthen its relevance across high-volume collection environments.
• Membrane Separation: Membrane systems provide selective separation through filtration characteristics and are important in therapeutic blood purification. Their strategic value increases where controlled removal of targeted plasma constituents supports specialized clinical protocols.

Application

The application comprises Renal Disorders, Hematological Disorders, Neurological Disorders, Autoimmune Disorders, and Other Applications. The segment is projected to grow at a CAGR of 8.1–9.1% during 2026–2034. Expansion reflects increasing use of therapeutic apheresis in specialized disease management, alongside donor applications that support blood-component availability. Clinical guidelines, specialist expertise, reimbursement, and availability of trained operators influence adoption.

• Renal Disorders: Therapeutic plasma-processing applications support selected renal indications, creating demand in specialized nephrology and hospital settings. Adoption depends strongly on clinical protocol, disease severity, and availability of experienced treatment centers.
• Hematological Disorders: Hematology remains strategically important because apheresis can support both component collection and selected therapeutic interventions. Specialized blood centers and tertiary hospitals form important demand centers.
• Neurological Disorders: Neurological indications represent an important therapeutic use area, particularly where plasma exchange is incorporated into specialist treatment pathways. Growth depends on clinical evidence, neurologist adoption, and access to trained apheresis teams.
• Autoimmune Disorders: Autoimmune conditions can require therapeutic removal of pathogenic plasma constituents in selected cases. Greater specialist awareness and protocol standardization can support utilization across tertiary-care environments.

Opportunity Snapshot

Apheresis Market Growth Drivers and Impact Analysis

Expansion of Therapeutic Apheresis in Complex Disease Management

Expanding adoption of therapeutic apheresis in select neurologic, autoimmune, renal, and hematologic disorders widens the clinical patient pool. The market benefit is felt most keenly where hospitals create specialist units that are equipped to handle repeat treatments and track anticoagulation, vascular access, fluid management, and replacement therapy. Increased specialization of the type also enables device utilization, since the installed systems have the flexibility to address a number of indications rather than one specific modality. This benefits equipment suppliers that offer technology platforms with protocol flexibility and quick procedure setup. The increased utilization then amplifies demand for disposables since every new treatment adds ongoing demands for tubing, filters, collection kits, and other procedure-related disposables.

Rising Demand for Plasma and Blood Components

The need for plasma and other blood components will drive continued investment in collecting equipment, especially for those health care organizations that are looking to make their blood product chain more resilient. Apheresis technology facilitates the selective separation of components, offering advantages over whole blood donation for specific cases. This offers an opportunity for blood centers to optimize collection capacity by maximizing component yields. The effect on the business includes equipment, disposables, anticoagulants, storage solutions, and contract services. It is especially significant in the case of plasma, as it requires reliable equipment operation and predictability in the consumption of consumables. The ability of manufacturers to deliver scalable platforms and standard processes for operators with local technical support will help them to cater to centers' increasing capacity.

Automation and Integration of Apheresis Workflows

The trend of automation is affecting the way equipment is bought by increasing the process consistency, reducing the dependency on the operators, and allowing better monitoring of the process variables. The modern systems are incorporating automatic control functions, alarms, data acquisition, and guidance of the process, which may help make complicated processes easy to handle. The effects on the market are especially important in the case of hospitals having difficulty recruiting highly qualified technical personnel because such systems will allow them to perform procedures in a standard fashion. The incorporation of the digital environment in hospitals provides good grounds for differentiation of the manufacturers in the matter of data management and remote services. At the same time, automatic processing of blood in the centers will increase their capacity and the predictability of the yield.

Apheresis Market Future Trends

Growth of Cell and Gene Therapy Collection Workflows

The development of cell and gene therapies is anticipated to stimulate new demand for controlled workflows for the collection and processing of cells. Leukapheresis machines can be considered the basis for collecting cellular material intended for advanced therapies. In this respect, it becomes more important to control the quality of collection, chain-of-identity controls, traceability, and standardized workflows. With the passage of time, the manufacturers may start building closer links between the apheresis machines, the technology of cell processing, documentation, and workflow at the therapy centers. Consequently, there will be a shift from the procurement of collection devices to the procurement of ecosystems. The suppliers who will manage to validate the collection devices for specific cellular applications will strengthen their position in the developing network of therapy centers.

Digitalized and Resource-Efficient Apheresis Platforms

The future systems would focus more on digital monitoring, automated parameter setting, remote diagnostics, and resource efficiency. The hospitals and blood centers are becoming more concerned with reducing the time consumed by the process, reducing the wastage of consumables, improving equipment usage, and measuring the performance of operations. Digital connection helps in managing the fleets centrally, performing preventive maintenance, and creating reports for various facilities. In addition, the disposables may be reengineered to reduce the use of materials without compromising their sterility and functionality. Such innovations will have an impact on procurement decisions since the total cost of ownership can be calculated beyond capital investment. The digital devices and optimized disposables can create strong supplier connections since the software, services, and disposables fit into the overall operating model.

Apheresis Market Opportunities

Expansion of Specialized Apheresis Capacity in Emerging Healthcare Systems

The new healthcare systems provide the chance to create therapeutic apheresis services at tertiary care hospitals and regional referral centers. The areas of investment include automatic systems, experienced clinical staff, a steady supply of disposables, technical maintenance, and standard treatment protocols. Companies entering the market could leverage partnerships with prominent hospitals, blood banks, and societies instead of focusing solely on distribution channels. Training in specific regions could solve the problem of the shortage of operators and prove the economic sense of platforms with multiple indications for use. Production or assembly in regions could minimize risks associated with supply chains when imported medical devices take a long time to be delivered to regions. The best chances would be those cases where the government develops its specialty care capabilities and private hospitals integrate their complex treatments into large-volume facilities.

Integrated Solutions for Cell Processing and Therapeutic Collections

Opportunities arise in linking apheresis collection with further cell processing and advanced therapies. Suppliers can capitalize by providing validated procedures for collection, traceability via the digital medium, compatibility with disposable supplies, training for operators, and data interfaces that make it easier to move cellular products through the rest of the process chain. Such integration can eliminate risk factors in transfer and increase process consistency at the facilities and among developers of advanced therapies. Collaboration with biotech firms, contract developers, and specialist hospitals will assist suppliers in validating systems for newer applications. Funding must be aimed at integration, quality systems, cybersecurity, and regulatory documentation, as opposed to simply equipment. Companies with already established collection systems have a definite advantage since existing systems serve as an access point to new cellular processes.

Recent Developments

• June 2026: Haemonetics Corporation announced a revised reportable-segment structure, combining its former Plasma and Blood Center businesses into a single Apheresis segment and renaming its Hospital segment MedSurg. The change aligns external reporting with the way the company manages its businesses, technologies, and served markets.
• November 2025: Terumo Blood and Cell Technologies, Inc. and Santersus AG announced an exclusive collaboration to advance therapeutic apheresis technology for sepsis. The partnership combines Santersus' NucleoCapture blood-purification technology with the Spectra Optia Apheresis System to support clinical development for critically ill patients.
• April 2025: Asahi Kasei Medical Co., Ltd. began operations following a corporate restructuring in which Asahi Kasei transferred a majority of its shares in Asahi Kasei Medical. The medical business continues to cover blood purification activities, including hemodialysis and therapeutic apheresis, while related life-science activities were reorganized separately.